ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2819

The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion

Beatrix Bartok, Division of Rheumatology, allergy and immunology, University of California, San Diego, La Jolla, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), synovial cells, synovial fluid and transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Fibroblast like synoviocytes (FLS) in RA possesses unique transformed phenotype, such as cartilage invasion that is maintained independent of cytokines and other inflammatory cells. However, the molecular mechanisms that regulate FLS behavior in RA are poorly understood. The transcriptional coactivator Yes-associated protein (YAP) was recently shown that is dysregulated in RA compared with OA FLS. Increased YAP activity might contribute to persistent activation and pathogenic behavior of RA FLS. Therefore, we assessed role of YAP in synoviocyte invasion.

Methods:

We used siRNA knock down and chemical inhibition to assess effect of YAP iactivation on RA FLS invasion. We used Verteporfin to inhibit YAP transcriptional activity. For siRNA knockdown, YAP and control siRNA were transfected using AMAXA technology. FLS invasion was studied using Matrigel coated transwells, 3 days following transfection. YAP inhibitor or vehicle was added to the upper chamber and PDGF was used as chemoattractant in the lower chamber. The cytoskeleton and focal adhesions were visualized with confocal microscopy using Rhodamin phalloidin and anti-Vinculin staining. MMP expression was measured using qPCR. 

Results:

The YAP inhibitor Verteporfin significantly decreased number of invading cells in a concentration dependent manner, with 65+5% inhibition at 0.1 uM (p< 0.02, n=3). Similar results were obtained when YAP was knockdown by siRNA. Cells with reduced YAP activity displayed 52+6% (p< 0.04, n=3) decrease in invasion through Matrigel matrix compared with scramble control. To determine effect of YAP inactivation on cytoskeleton and focal adhesion formation, cells were stained with phalloidin and anti-Viculin. RA FLS treated with the YAP inhibitor Verteporfin displayed diminished stress fiber formation and decrease in focal adhesion formation by 56+5% (p<0.04, n=3) visualized with confocal microscopy. Similar findings were obtained when YAP was inactivated by siRNA knock down. To determine the effect on MMP production cells were stimulated with TNF and qPCR was performed for MMP1, 2, 3, 9 and MT1MMP. mRNA levels for MMP1 and MMP3 were significantly lower in YAP deficient cells compared with scramble control (P<0.03 and p<0.05, n=3), while MMP2,9 and MT1MMP mRNA were unchanged. Similar findings were obtained using chemical inhibition with Verteporfin.

Conclusion:

YAP is a major regulator of RA FLS invasion by modulating focal adhesion formation and MMP production. These observations, together with our previous findings that increased YAP activity in RA FLS compared with OA suggest that YAP activity might contribute to persistent activation and pathogenic behavior of RA FLS. Therefore, modulating YAP pathway might represent a novel therapeutic approach for RA.


Disclosure:

B. Bartok,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-yap-pathway-regulates-fibroblast-like-synoviocyte-invasion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology